Affiliation:
1. Center on Reproductive Health, Law, and Policy University of California Los Angeles Los Angeles California USA
2. Department of Obstetrics, Gynecology, & Reproductive Sciences University of California San Francisco, Advancing New Standards in Reproductive Health Oakland California USA
Abstract
AbstractOn January 30, 2024, over 300 researchers filed an amicus brief in FDA v. Alliance for Hippocratic Medicine, a United States (US) Supreme Court case concerning the regulatory status of mifepristone, one of two drugs used in medication abortion. In this Comment we summarize the legal challenge, responses from the FDA and drug manufacturer to these challenges, oral arguments presented before the Court, and the implications of the Court's decision on access to mifepristone in the US. We also summarize the content of the accompanying amicus brief.
Reference20 articles.
1. Guttmacher Institute JonesRK Friedrich‐KarnikA.Medication abortion accounted for 63% of all US abortions in 2023—an increase from 53% in 2020.2024https://www.guttmacher.org/2024/03/medication‐abortion‐accounted‐63‐all‐us‐abortions‐2023‐increase‐53‐2020
2. Medical methods for first trimester abortion
3. Mifepristone With Buccal Misoprostol for Medical Abortion
4. First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review
5. Alliance for Hippocratic Medicine v.Food and Drug Administration 668 F. Supp. 3d 507.(N.D. Tex. 2023).